Skip to main navigation Skip to search Skip to main content

Interferon α 2b treatment for residual ocular surface squamous neoplasia unresponsive to excision, cryotherapy and mitomycin-C

  • Arie Y. Nemet*
  • , Vidushi Sharma
  • , Ross Benger
  • *Corresponding author for this work
  • South Eastern Sydney and Illawarra Area Health Service

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Three patients had residual or recurrent tumour following excision of large ocular surface squamous neoplasia (OSSN) lesions, which did not resolve despite the use of adjunctive cryotherapy and topical mitomycin-C therapy. The residual tumour was treated with topical or subconjunctival injectable interferon α 2b. All three eyes had complete resolution of the OSSN lesions after an average of 6 weeks (range 4-8 weeks) of treatment with interferon α 2b. No regrowth was seen during the follow-up period of 22.7 ± 32.3 months (range 5-60 months). No adverse reactions or complaints were reported during and following interferon use, and previous symptoms from mitomycin-C treatment resolved completely. In these patients subconjunctival or topical interferon was an effective and safe treatment for residual OSSN. Longer follow up is required to confirm the long-term efficacy in prevention of recurrences.

Original languageEnglish
Pages (from-to)375-377
Number of pages3
JournalClinical and Experimental Ophthalmology
Volume34
Issue number4
DOIs
StatePublished - May 2006
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Carcinoma in situ
  • Fluorouracil
  • Interferon type II
  • Mitomycin-c

Fingerprint

Dive into the research topics of 'Interferon α 2b treatment for residual ocular surface squamous neoplasia unresponsive to excision, cryotherapy and mitomycin-C'. Together they form a unique fingerprint.

Cite this